Non-anticoagulant effects of heparin: An overview

Handbook of Experimental Pharmacology

Volumn 207, Issue , 2012, Pages 281-305

  Lever, Rebecca ^a   Page, Clive P ^b  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cancer; Inflammation; Inflammatory disease; Non anticoagulant effects

Indexed keywords

ANTITHROMBIN; CD31 ANTIGEN; FONDAPARINUX; HEPARANASE; HEPARIN; L SELECTIN; LOW MOLECULAR WEIGHT HEPARIN; PADGEM PROTEIN; PROTEOHEPARAN SULFATE; THROMBIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ALLERGIC ENCEPHALOMYELITIS; ALLERGIC RHINITIS; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTHRITIS; ARTICLE; ASTHMA; BLEEDING; BRAIN ISCHEMIA; BRONCHUS HYPERREACTIVITY; BURN; CELL ADHESION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DELAYED HYPERSENSITIVITY; ENTERITIS; GRAFT REJECTION; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; INTERSTITIAL CYSTITIS; LEUKOCYTE ACTIVATION; LUNG BURN; MAST CELL DEGRANULATION; METASTASIS INHIBITION; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; SURVIVAL RATE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS; TISSUE REPAIR; ULCERATIVE COLITIS; VENOUS THROMBOEMBOLISM; WOUND HEALING; DRUG EFFECT; REVIEW;

HEPARIN; HUMANS; INFLAMMATION; NEOPLASMS; WOUND HEALING;

EID: 84861840833     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-23056-1_12     Document Type: Article

References (128)

1. Abrink M, Grujic M, Pejler G (2004) Serglycin is essential for maturation of mast cell secretory granule. J Biol Chem 279:40897-40905
2. Ahmed T, Abraham WM, D'Brot J (1992) Effects of inhaled heparin on immunologic and nonimmunologic bronchoconstrictor responses in sheep. Am Rev Respir Dis 145:566-570
3. Ahmed T, Garrigo J, Danta I (1993) Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin. N Engl J Med 329:90-95
4. Ahmed T, Syriste T, Mendelssohn R, Sorace D, Mansour E, Lansing M, Abraham WM, Robinson MJ (1994) Heparin prevents antigen-induced airway hyperresponsiveness: interference with IP3-mediated mast cell degranulation? J Appl Physiol 76:893-901
5. Ahmed T, Campo C, Abraham MK, Molinari IF, Abraham WM, Ashkin D, Syriste T, Andersson LO, Svahn CM (1997) Inhibition of antigen-induced acute bronchoconstriction, airway hyperresponsiveness, and mast cell degranulation by a nonanticoagulant heparin - comparison with a low molecular weight heparin. Am J Respir Crit Care Med 155:1848-1855
6. Aki EA, van Doormaal FF, Barba M, Kamath G, Kim SY, Kuipers S, Middeldorp S, Yosuico V, Dickinson HO, Sch€unemann HJ (2007) Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. Cochrane Database Syst Rev 3:CD006652
7. Alonso DF, Bertolesi GE, Farias EF, Eijan AM, Joffe EBD, De Cidre LL (1996) Antimetastatic effects associated with anticoagulant properties of heparin and chemically modified heparin species in a mouse mammary tumor model. Oncol Rep 3:219-222
8. Amirkhosravi A, Meyer T, Amaya M, Davila M, Mousa SA, Robson T, Francis JL (2007) The role of tissue factor pathway inhibitor in tumor growth and metastasis. Semin Thromb Hemost 33:643-652
9. Antczak M, Kuna P (1995) Heparin inhibits allergen induced airway response in asthmatics. Results of a double blind placebo-controlled, crossover study. J Allergy Clin Immunol 95:386 (Abstract)
10. Baer CL, Bennett WM, Folwick DA, Erickson RS (1996) Effectiveness of a jet injection system in administering morphine and heparin to healthy adults. Am J Crit Care 5:42-48
11. Bai S, Ahsan F (2009) Synthesis and evaluation of pegylated dendrimeric nanocarrier for pulmonary delivery of low molecular weight heparin. Pharm Res 26:539-548
12. Bai S, Ahsan F (2010) Inhalable liposomes of low molecular weight heparin for the treatment of venous thromboembolism. J Pharm Sci 99:4554-4564
13. Bai S, Gupta V, Ahsan F (2010) Inhalable lactose-based dry powder formulations of low molecular weight heparin. J Aerosol Med Pulm Drug Deliv 23:97-104
14. Bar-Ner M, Eldor A, Wasserman L, Matzner Y, Cohen IR, Fuks Z, Vlodavsky I (1987) Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin species. Blood 70:551-557
15. Basche M, Gustafson DL, Holden SN, O'Bryant CL, Gore L, Witta S, Schultz MK, Morrow M, Levin A, Creese BR, Kangas M, Roberts K, Nguyen T, Davis K, Addison RS, Moore JC, Eckhardt SG (2006) A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors. Clin Cancer Res 12:5471-5480
16. Baughman RA, Kapoor SC, Agarwal RK, Kisicki J, Catella-Lawson F, FitzGerald GA (1998) Oral delivery of anticoagulant doses of heparin. A randomized, double-blind, controlled study in humans. Circulation 98:1610-1615
17. Bazzoni G, Nunez AB, Mascellani G, Bianchini P, Dejana E, Del Maschio A (1992) Effect of heparin, dermatan sulfate, and related oligo-derivatives on human polymorphonuclear leukocyte functions. J Lab Clin Med 121:268-275
18. Becker M, Menger MD, Lehr HA (1994) Heparin-released superoxide dismutase inhibits postischemic leukocyte adhesion to venular endothelium. Am J Physiol 267:H925-930
19. Bendstrup KE, Chambers CB, Jensen JI, Newhouse MT (1999) Lung deposition and clearance of Inhaled 99mTc-heparin in healthy volunteers. Am J Respir Crit Care Med 160:1653-1658
20. Berkowitz SD, Marder VJ, Kosutic G, Baughman RA (2003) Oral heparin administration with a novel drug delivery agent (SNAC) in healthy volunteers and patients undergoing elective total hip arthroplasty. J Thromb Haemost 1:1914-1919
21. Bono F, Rigon P, Lamarche I, Savi P, Salel V, Herbert J-M (1997) Heparin inhibits the binding of basic fibroblast growth factor to cultured human aortic smooth-muscle cells. Biochem J 326:661-668
22. Borsig L (2010) Antimetastatic activities of heparins and modified heparins: experimental evidence. Thromb Res 125:S66-S71
23. Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A (2001) Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA 98:3352-3357
24. Bowler SD, Smith SM, Laverombe PS (1993) Heparin inhibits the immediate response to antigen in the skin and lungs of allergic subjects. Am Rev Respir Dis 147:160-163
25. Brown RA, Lever R, Jones NA, Page CP (2003) Effects of heparin and related molecules upon neutrophil aggregation and elastase release in vitro. Br J Pharmacol 139:845-853
26. Brown RA, Allegra L, Matera MG, Page CP, Cazzola M (2006) Additional clinical benefit of enoxaparin in COPD patients receiving salmeterol and fluticasone propionate in combination. Pulm Pharmacol Ther 19:419-424
27. Brunnee T, Reddigan SR, Shibayama Y, Kaplan AP, Silverberg M (1997) Mast cell derived heparin activates the contact system: A link to kinin generation in allergic reactions. Clin Exp Allergy 27:653-663
28. Cancio LC (2009) Airway management and smoke inhalation injury in the burn patient. Clin Plast Surg 36:555-567
29. Carr J (1979) The anti-inflammatory action of heparin: Heparin as an antagonist to histamine, bradykinin and prostaglandin E1. Thromb Res 16:507-516
30. Casu B, Vlodavsky I, Sanderson RD (2008) Non-anticoagulant heparins and inhibition of cancer. Pathophysiol Haemost Thromb 36:195-203
31. Chande N, MacDonald JW, Macdonald JK (2008) Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2:CD006774
32. Chen G, Wang D, Vikramadithyan R, Yagyu H, Saxena U, Pillarisetti S, Goldberg IJ (2004) Inflammatory cytokines and fatty acids regulate endothelial cell heparanase expression. Biochemistry 43:4971-4977
33. Clowes AW, Karnovsky MJ (1977) Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 265:625-626
34. Cole GJ, Loewy A, Glaser L (1986) Neuronal cell-cell adhesion depends on interactions of N-CAM with heparin-like molecules. Nature 320:445-447
35. Cribbs RK, Luquette MH, Besner GE (1998) Acceleration of partial-thickness burn wound healing with topical application of heparin-binding EGF-like growth factor (HB-EGF). J Burn Care Rehabil 19:95-101
36. Cribbs RK, Harding PA, Luquette MH, Besner GE (2002) Endogenous production of heparinbinding EGF-like growth factor during murine partial-thickness burn wound healing. J Burn Care Rehabil 23:116-125
37. Darien BJ, Fareed J, Centgraf KS, Hart AP, MacWilliams PS, Clayton MK, Wolf H, Kruse-Elliott KT (1998) Low molecular weight heparin prevents the pulmonary hemodynamic and pathomorphologic effects of endotoxin in a porcine acute lung injury model. Shock 9:274-281
38. Davids H, Ahmed A, Oberholster A, van der Westhuizen C, Mer M, Havlik I (2010) Endogenous heparin levels in the controlled asthmatic patient. S Afr Med J 100:307-308
39. De Lisser HM, Horng CY, Newman PJ, Muller WA, Buck CA, Albelda SM (1993) Platelet/ endothelial cell adhesion molecule-1 (CD31)-mediated cellular aggregation involves cell surface glycosaminoglycans. J Biol Chem 268:16037-16046
40. Diamant Z, Timmers MC, Van Der Veen H, Page CP, Van Der Meer FJM, Sterk PJ (1996) Effect of inhaled heparin on allergen-induced early and late asthmatic responses in patients with atopic asthma. Am J Respir Crit Care Med 153:1790-1795
41. Diamond MS, Alon R, Parkos CA, Quinn MT, Springer TA (1995) Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b/CD18). J Cell Biol 130:1473-1482
42. Dolowitz DA, Dougherty TF (1960) The use of heparin as an anti-inflammatory agent. Laryngoscope 70:873-874
43. Dolowitz DA, Dougherty TF (1965) The use of heparin in the control of allergies. Ann Allergy 23:309-313
44. Dragstedt CA, Wells JA, Rocha E, Silva M (1942) Inhibitory effect of heparin upon histamine release by trypsin, antigen, and protease. Proc Soc Exp Biol Med 51:191-192
45. Edovitsky E, Elkin M, Zcharia E, Peretz T, Vlodavsky I (2004) Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J Natl Cancer Inst 96:1194-1195
46. Edovitsky E, Lerner I, Zcharia E, Peretz T, Vlodavsky I, Elkin M (2006) Role of endothelial heparanase in delayed-type hypersensitivity. Blood 107:3609-3616
47. Engelberg H (1999) Actions of heparin that may affect the malignant process. Cancer 85:257-272
48. Engelberg H (2001) Endogenous heparin activity deficiency: the 'missing link' in atherogenesis? Atherosclerosis 159:253-260
49. Evangelista V, Piccardoni P, Maugeri N, De Gaetano G, Cerletti C (1992) Inhibition by heparin of platelet activation induced by neutrophil-derived cathepsin G. Eur J Pharmacol 216: 401-405
50. Evans RC, Wong VS, Morris AI, Rhodes JM (1997) Treatment of corticosteroid-resistant ulcerative colitis with heparin - a report of 16 cases. Aliment Pharmacol Ther 11:1037-1040
51. Fairbanks MB, Mildner AM, Leone JW, Cavey GS, Mathews WR, Drong RF, Slightom JL, Bienkowski MJ, Smith CW, Bannow CA, Heinrikson RL (1999) Processing of the human heparanase precursor and evidence that the active enzyme is a heterodimer. J Biol Chem 274: 29587-29590
52. Ferreira Chacon JM, Mello de Andrea LM, Blanes L, Ferreira LM (2010) Effects of topical application of 10,000 IU heparin on patients with perineal dermatitits and second-degree burns treated in a public pediatric hospital. J Tissue Viability 19:150-158
53. Forsberg E, Pejler G, Ringvall M, Lunderius C, Tomasini-Johansson B, Kusche-Gullberg M, Eriksson I, Ledin J, Hellman L, Kjellén L (1999) Abnormal mast cells in mice deficient in a heparin-synthesizing enzyme. Nature 400:773-776
54. Fredens K, Dahl R, Venge P (1991) In vitro studies of the interaction between heparin and eosinophil cationic protein. Allergy 46:27-29
55. Freischlag JA, Colburn MD, Quinones-Baldrich WJ, Moore WS (1992) Heparin, urokinase, and ancrod alter neutrophil function. J Vasc Surg 16:565-572
56. Fritzsche J, Alban S, Ludwig RJ, Rubant S, Boehncke W-H, Schumacher G, Bendas G (2006) The influence of various structural parameters of semisynthetic sulfated polysaccharides on the P-selectin inhibitory capacity. Biochem Pharmacol 72:474-485
57. Fryer A, Huang YC, Rao G, Jacoby D, Mancilla E, Whorton R, Piantadosi CA, Kennedy T, Hoidal J (1997) Selective O-desulfation produces nonanticoagulant heparin that retains pharmacological activity in the lung. J Pharmacol Exp Ther 282:208-219
58. Gaffney A, Gaffney P (1996) Rheumatoid arthritis and heparin. Br J Rheumatol 35:808
59. Gaffney PR, O'Leary J, Doyle CT, Gaffney A, Hogan J, Smew F, Annis P (1991) Response to heparin in patients with ulcerative colitis. Lancet 337:238-239
60. Gaffney PR, Doyle CT, Gaffney A, Hogan J, Hayes DP, Annis P (1995) Paradoxical response to heparin in 10 patients with ulcerative colitis. Am J Gastroenterol 90:220-223
61. Gallagher JT (2011) Heparan sulphate: A heparin in miniature. In: Lever R, Mulloy B, Page CP (eds) Heparin - a century of progress. Springer, Heidelberg
62. Ghosh TK, Eis PS, Mullaney JM, Ebert CL, Gill DL (1988) Competitive, reversible and potent antagonism of inositol 1,4,5-triphosphate-activated calcium release by heparin. J Biol Chem 263:11075-11079
63. Gilat D, Hershkoviz R, Mekori YA, Vlodavsky I, Lider O (1994) Regulation of adhesion of CD4+ T lymphocytes to intact or heparinase-treated subendothelial extracellular matrix by diffusible or anchored RANTES and MIP-1a. J Immunol 153:4899-4906
64. Giuffrè L, Cordey A-S, Monai N, Tardy Y, Schapira M, Spertini O (1997) Monocyte adhesion to activated aortic endothelium: role of L-selectin and heparan sulfate proteoglycans. J Cell Biol 136:945-956
65. Gonze MD, Salartash K, Sternbergh WC, Baughman RA, Leone-Bay A, Money SR (2000) Orally administered unfractionated heparin with carrier agent is therapeutic for deep venous thrombosis. Circulation 101:2658-2661
66. Gorski A, Lao M, Gradowska L, Nowaczyk M, Wasik M, Lagodzinski Z (1991) New strategies of heparin treatment used to prolong allograft survival. Transplant Proc 23:2251-2252
67. Gray E, Mulloy B, Barrowcliffe TW (2008) Heparin and low-molecular-weight heparin. Thromb Haemost 99:807-818
68. Green WF, Konnaris K, Woolcock AJ (1993) Effect of salbutamol, fenoterol, and sodium cromoglycate on the release of heparin from sensitized human lung fragments challenged with Dermatophagoides pteronyssinus allergen. Am J Respir Cell Mol Biol 8:518-521
69. Guyton JR, Rosenberg RD, Clowes AW, Karnovsky (1980) Inhibition of rat arterial smooth muscle cell proliferation by heparin: in vivo studies with anticoagulant and nonanticoagulant heparin. Circ Res 46:625-634
70. Handel TM, Johnson Z, Crown SE, Lau EK, Proudfoot AE (2005) Regulation of protein function by glycosaminoglycans - as exemplified by chemokines. Annu Rev Biochem 74:385-410
71. Hettiarachchi RJ, Smorenburg SM, Ginsberg J, Levine M, Prins MH, B€uller HR (1999) Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost 82:947-952
72. Hiebert LM (2002) Oral heparins. Clin Lab 48:111-116
73. Hiebert LM, Ping T, Wice SM (2008) Enhanced antithrombotic effects of unfractionated heparin in rats after repeated oral doses and its relationship to endothelial heparin concentration. Br J Pharmacol 153:1177-1184
74. Hollingsworth SJ, Hoque K, Linnard D, Corry DG, Barker SG (2000) Delivery of low molecular weight heparin for prophylaxis against deep vein thrombosis using a novel, needle-less injection device (J-Tip). Ann R Coll Surg Engl 82:428-431
75. Hulett MD, Freeman C, Hamdorf BJ, Baker RT, Harris MJ, Parish CR (1999) Cloning of mammalian heparanase: An essential enzyme involved in tumor invasion and metastasis. Nat Med 5:803-809
76. Hulett MD, Hornby JR, Ohms SJ, Zuegg J, Freeman C, Gready JE, Parish CR (2000) Identification of active-site residues of the pro-metastatic endoglycosidase heparanase. Biochemistry 39:15659-15667
77. Humphries DE, Wong GW, Friend DS, Gurish MF, Qiu WT, Huang C, Sharpe AH, Stevens RL (1999) Heparin is essential for the storage of specific granule proteases in mast cells. Nature 400:769-772
78. Inase N, Schreck RE, Lazarus SC (1993) Heparin inhibits histamine release from canine mast cells. Am J Physiol 264:L387-L390
79. Jaques LB (1979) Heparins - anionic polyelectrolyte drugs. Pharmacol Rev 31:99-167
80. Johnson Z, Kosco-Vilbois MH, Herren S, Cirillo R, Muzio V, Zaratin P, Carbonatto M, Mack M, Smailbegovic A, Rose M, Lever R, Page C, Wells TN, Proudfoot AE (2004) Interference with heparin binding and oligomerization creates a novel anti-inflammatory strategy targeting the chemokine system. J Immunol 173:5776-5785
81. Jones H, Paul W, Page CP (2002) The effects of heparin and related molecules on vascular permeability and neutrophil accumulation in rabbit skin. Br J Pharmacol 135:469-479
82. Joyce JA, Freeman C, Meyer-Morse N, Parish CR, Hanahan D (2005) A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene 24:4037-4051
83. Kallapur SG, Akeson RA (1992) The neural cell adhesion molecule (NCAM) heparin binding domain binds to cell surface heparan sulfate proteoglycans. J Neurosci Res 33:538-548
84. Kanabar V, Hirst SJ, O'Connor BJ, Page CP (2005) Some structural determinants of the antiproliferative effect of heparin-like molecules on human airway smooth muscle. Br J Pharmacol 146:370-377
85. Karnovsky MJ, Wright TC Jr, Castellot JJ Jr, Choay J, Lormeau JC, Petitou M (1989) Heparin, heparan sulfate, smooth muscle cells, and atherosclerosis. Ann NY Acad Sci 556:268-281
86. Kennedy TP (1994) Use of heparin to inhibit interleukin-8. International patent application, WO94/18989
87. Khorana AA, Sahni A, Altland OD, Francis CW (2003) Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight. Arterioscler Thromb Vasc Biol 23:2110-2115
88. Kilfeather SA, Tagoe S, Perez AC, Okona-Mensah K, Matin R, Page CP (1995) Inhibition of serum-induced proliferation of bovine tracheal smooth muscle cells in culture by heparin and related glycosaminoglycans. Br J Pharmacol 114:1442-1446
89. Kilgore KS, Tanhehco EJ, Naylor KB, Lucchesi BR (1999) Ex vivo reversal of heparin-mediated cardioprotection by heparinase after ischemia and reperfusion. J Pharmacol Exp Therapeut 290:1041-1047
90. Kiselyov VV, Berezin V, Maar TE, Soroka V, Edvardsen K, Schousboe A, Bock E (1997) The first immunoglobulin-like neural cell adhesion molecule (NCAM) domain is involved in doublereciprocal interaction with the second immunoglobulin-like NCAM domain and in heparin binding. J Biol Chem 272:10125-10134
91. Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A (1998) Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. J Clin Invest 101:877-889
92. Kovanen PT (2009) Mast cells in atherogenesis: Actions and reactions. Curr Atheroscler Rep 11:214-219
93. Kuderer NM, Khorana AA, Lyman GH, Francis CW (2007) A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer 110:1149-1161
94. Kussie PH, Hulmes JD, Ludwig DL, Patel S, Navarro EC, Seddon AP, Giorgio NA, Bohlen P (1999) Cloning and functional expression of a human heparanase gene. Biochem Biophys Res Commun 261:183-187
95. Laghi-Pasini F, Pasqui AL, Ceccatelli L, Capecchi PL, Orrico A, Di Perri T (1984) Heparin inhibition of polymorphonuclear leukocyte activation in vitro. A possible pharmacological approach to granulocyte-mediated vascular damage. Thromb Res 35:527-537
96. Lawrence MB, Springer TA (1991) Leukocytes roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins. Cell 65:859-873
97. Leculier C, Benzerara O, Couprie N, Francina A, Lasne Y, Archimbaud E, Fiere D (1992) Specific binding between human neutrophils and heparin. Br J Haematol 81:81-85
98. Lever R, Page CP (2002) Novel drug development opportunities for heparin. Nat Rev Drug Discov 1:140-148
99. Lever R, Hoult JRS, Page CP (2000) The effects of heparin and related molecules upon the adhesion of human polymorphonuclear leucocytes to vascular endothelium in vitro. Br J Pharmacol 129:533-540
100. Lever R, Lo WT, Faraidoun M, Amin V, Brown RA, Gallagher J, Page CP (2007) Sizefractionated heparins have differential effects on human neutrophil function in vitro. Br J Pharmacol 151:837-843
101. Lever R, Smailbegovic A, Page CP (2010) Locally available heparin modulates inflammatory cell recruitment in a manner independent of anticoagulant activity. Eur J Pharmacol 630:137-144
102. Ley K, Cerrito M, Arfors K-E (1991) Sulfated polysaccharides inhibit leukocyte rolling in rabbit mesentery venules. Am J Physiol 260:H1667-H1673
103. Li L-F, Huang C-C, Lin H-C, Tsai Y-H, Quinn DA, Liao S-K (2009) Unfractionated heparin and enoxaparin reduce high-stretch ventilation augmented lung injury: A prospective, controlled animal experiment. Crit Care 13:R108
104. Lider O, Baharav E, Mekori YA, Miller T, Naparstek Y, Vlodavsky I, Cohen IR (1989) Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparin. J Clin Invest 83:752-756
105. Lider O, Mekori YA, Miller T, Bar-Tana R, Vlodavsky I, Baharav E, Cohen IR, Naparstek Y (1990) Inhibition of T lymphocyte heparanase by heparin prevents T cell migration and T cellmediated immunity. Eur J Immunol 20:493-499
106. Lilly JD, Parsons CL (1990) Bladder surface glycosaminoglycans is a human epithelial permeability barrier. Surg Gynaecol Obstet 171:493-496
107. Maarsingh H, de Boer J, Kauffman HF, Zaagsma J, Meurs H (2004) Heparin normalizes allergeninduced nitric oxide deficiency and airway hyperresponsiveness. Br J Pharmacol 142:1293-1299
108. Marchetti M, Vignoli A, Russo L, Balducci D, Pagnoncelli M, Barbui T, Falanga A (2008) Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin. Thromb Res 121:637-645
109. Matzner Y, Marx G, Drexler R, Eldor A (1984) The inhibitory effect of heparin and related glycosaminoglycans on neutrophil chemotaxis. Thromb Haemost 52:134-137
110. Matzner Y, Vlodavsky I, Bar-Ner M, Ishai-Michaeli R, Tauber AI (1992) Subcellular localization of heparanase in human neutrophils. J Leukoc Biol 51:519-524
111. McCaffrey TA, Falcone DJ, Brayton CF, Agarwal LA, Welt FG, Weksler BB (1989) Transforming growth factor-b activity is potentiated by heparin via dislocation of the transforming growth factor-b/a2-macroglobulin inactive complex. J Cell Biol 109:441-448
112. McKenzie EA (2007) Heparanase: A target for drug discovery in cancer and inflammation. Br J Pharmacol 151:1-14
113. McKenzie E, Tyson K, Stamps A, Smith P, Turner P, Barry R, Hircock M, Patel S, Barry E, Stubberfield C, Terrett J, Page M (2000) Cloning and expression profiling of hpa2, a novel mammalian heparanase family member. Biochem Biophys Res Commun 276:1170-1177
114. Mehrad B, Keane MP, Strieter RM (2007) Chemokines as mediators of angiogenesis. Thromb Haemost 97:755-762
115. Michell NP, Lalor P, Langman MJ (2001) Heparin therapy for ulcerative colitis? Effects and mechanisms. Eur J Gastroenterol Hepatol 13:449-456
116. Miller MD, Krangel MS (1992) Biology and biochemistry of the chemokines: A family of chemotactic and inflammatory cytokines. Crit Rev Immunol 12:17-46
117. Miller AC, Rivero A, Ziad S, Smith DJ, Elamin EM (2009) Influence of nebulized unfractionated heparin and N-acetylcysteine in acute lung injury after smoke inhalation injury. J Burn Care Res 30:249-256
118. Mousa SA (2010) Heparin and low-molecular weight heparins in thrombosis and beyond. Methods Mol Biol 663:109-132
119. Mousa SA, Fareed J, Iqbal O, Kaiser B (2004) Tissue factor pathway inhibitor in thrombosis and beyond. Methods Mol Med 93:133-155
120. Mousa SA, Linhardt R, Francis JL, Amirkkhosravi A (2006) Anti-metastatic effect of a nonanticoagulant low-molecular-weight heparin versus the standard low-molecular weight heparin, enoxaparin. Thromb Haemost 96:816-821
121. Mulloy B, Crane DT, Drake AF, Davies DB (1996) The interaction between heparin and polylysine: A circular dichroism and molecular modelling study. Braz J Med Biol Res 29:721-729
122. Muramatsu T, Muramatsu H (2008) Glycosaminoglycan-binding cytokines as tumor markers. Proteomics 8:3350-3359
123. Murch SH, MacDonald TT, Walker-Smith JA, Levin M, Lionetti P, Klein NJ (1993) Disruption of sulphated glycosaminoglycans in intestinal inflammation. Lancet 341:711-714
124. Mustafa F, Yang T, Khan MA, Ahsan F (2004) Chain length-dependent effects of alkylmaltosides on nasal absorption of enoxaparin. J Pharm Sci 93:675-683
125. Nakajima M, Irimura T, Nicolson GL (1988) Heparanases and tumor metastasis. J Cell Biochem 36:157-167
126. Naparstek E, Slavin S, Weiss L, Sidi H, Ohana M, Reich S, Vlodavsky I, Cohen IR, Naparstek Y (1993) Low-dose heparin inhibits acute graft versus host disease in mice. Bone Marrow Transplant 12:185-189
127. Nelson RM, Cecconi O, Roberts WG, Aruffo A, Linhardt RJ, Bevilacqua MP (1993) Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 82:3253-3258
128. Niers TM, Klerk CP, DiNisio M, Van Noorden CJ, B€uller HR, Reitsma PH, Richel DJ (2007) Mechanisms of heparin induced anti-cancer activity in experimental cancer models. Crit Rev Oncol Hematol 33:358-368